Veraxa Biotech
VRXA
8 hedge funds and large institutions have $1.66M invested in Veraxa Biotech in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
652% more capital inflows, than outflows
Capital inflows: $2.09M | Capital outflows: $278K
0.6% more ownership
Funds ownership: 0.34% → 0.94% (+0.6%)
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Yorkville Advisors Global
Mountainside,
New Jersey
|
+$1.87M |
| 2 |
Cantor Fitzgerald
New York
|
+$126K |
| 3 |
Millennium Management
New York
|
+$55K |
| 4 |
Marex Group
London,
|
+$39.6K |
| 5 |
JP Morgan Chase
New York
|
+$212 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$153K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$50.8K |
| 3 |
HRT Financial
New York
|
-$35K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.4K |
| 5 |
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$19.3K |
VRXA Hedge Fund Activity: Q3 2026 in Review
8 of the 8,172 institutional investors tracked by Wall St. Rank reported a position in Veraxa Biotech (VRXA) for Q3 2026, worth a combined $1.66M — up 177% from $600K a quarter earlier.
Fund positioning in VRXA was balanced in Q3 2026: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Yorkville Advisors Global, opening a new position worth an estimated $1.87M. The largest seller was UBS Group, cutting an estimated $153K.
- 8 institutional investors held Veraxa Biotech (VRXA) as of Q3 2026, unchanged from Q2 2026.
- Funds reported $1.66M of Veraxa Biotech stock for Q3 2026, up 177% quarter-over-quarter.
- 4 funds opened new Veraxa Biotech positions in Q3 2026 and 4 closed out, a net change of 0 holders.
- The largest Veraxa Biotech buyer in Q3 2026 was Yorkville Advisors Global, an estimated $1.87M added.
- The largest Veraxa Biotech seller in Q3 2026 was UBS Group, an estimated $153K sold.
Based on aggregated 13F filings for Q3 2026.